NSUN2/ALYREF axis-driven m5C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer
Cancer Immunology, Immunotherapy · 03.03.2025 · 74 (4)
DOI: 10.1007/s00262-025-03986-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 03.03.2025. Verfasst von Yiran Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, No. 241 West Huaihai Road, Sha…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Methyltransferases. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nurture projects for basic research of Shanghai Chest Hospital, National Natural Science Foundation of China, Shanghai Science and Technology Committee Rising-Star Program.
Abstract (Originalsprache)
Non-small-cell lung cancer (NSCLC) represents a highly prevalent form of malignancy. 5-methylcytosine (m 5 C) methylation functions as a key post-transcriptional regulatory mechanism linked to cancer progression. The persistent expression of PD-L1 in tumor cells plays a pivotal role in facilitating immune evasion and promoting T-cell exhaustion. However, the involvement of m 5 C in NSCLC immune evasion remains inadequately understood. This study seeks to explore the function of the m 5 C methyltransferase NSUN2 in modulating PD-L1 expression and facilitating immune evasion in NSCLC. Our findings indicate elevated levels of NSUN2 and ALYREF in NSCLC, and both promote the growth of NSCLC cells and the progression of lung cancer. Moreover, the expression of PD-L1 in NSCLC tissues positively correlates with NSUN2 and ALYREF expression. We then discovered that PD-L1 acts as a downstream target of NSUN2-mediated m 5 C modification in NSCLC cells. Knocking down NSUN2 significantly reduces m 5 C modification of PD-L1 mRNA, thereby decreasing its stability via the m 5 C reader ALYREF-dependent manner. Furthermore, inhibiting NSUN2 enhanced CD8 + T-cell activation and infiltration mediated by PD-L1, thereby boosting antitumor immunity, as confirmed in both in vitro and in vivo experiments. Collectively, these results suggested that NSUN2/ALYREF/PD-L1 axis plays a critical role in promoting NSCLC progression and tumor cell immune suppression, highlighting its potential as a novel therapeutic strategy for NSCLC immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, No. 241 West Huaihai Road, Shanghai, 200030, China.
- Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, No. 241 West Huaihai Road, Shanghai, 200030, China.
- Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, No. 241 West Huaihai Road, Shanghai, 200030, China. xuyunhua1015@hotmail.com.
- Department of Clinical Laboratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, No. 241 West Huaihai Road, Shanghai, 200030, China. malifang0606118@126.com.
Förderung
- Nurture projects for basic research of Shanghai Chest Hospital
- National Natural Science Foundation of China
- Shanghai Science and Technology Committee Rising-Star Program
- Talent Training Plan of Shanghai Chest Hospital in 2022
- High-level Local University Construction-Shanghai Jiao Tong University School of Medicine of Linghang pandeng Program
Zitieren
APA
Yang, Y., Cao, L., Xu, X., Li, D., Deng, Y., Li, L., Zeng, B., Jiang, H., Shan, L., Huang, Y., Xu, Y., & Ma, L. (2025). NSUN2/ALYREF axis-driven m5C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer. Cancer Immunology, Immunotherapy, 74(4). https://doi.org/10.1007/s00262-025-03986-5
Vancouver
Yang Y, Cao L, Xu X, Li D, Deng Y, Li L, et al. NSUN2/ALYREF axis-driven m5C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer. Cancer Immunology, Immunotherapy. 2025;74(4). doi:10.1007/s00262-025-03986-5
BibTeX
@article{Yang2025,
author = {Yang, Yiran and Cao, Leiqun and Xu, Xin and Li, Dan and Deng, Yiran and Li, Lan and Zeng, Bingjie and Jiang, Haixia and Shan, Liang and Huang, Yiwen and Xu, Yunhua and Ma, Lifang},
title = {NSUN2/ALYREF axis-driven m5C methylation enhances PD-L1 expression and facilitates immune evasion in non-small-cell lung cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
volume = {74},
number = {4},
doi = {10.1007/s00262-025-03986-5}
}
EUVIMED